🚨 Everything is back in stock — all peptides available now 🚨

Retatrutide vs tirzepatide

Written and maintained by the AVERON Research Desk · Last reviewed September 2026

Retatrutide and tirzepatide are both once-weekly compounds developed by Eli Lilly, and both are studied for obesity and type 2 diabetes. They are closely related, and they are often compared. The single most important difference between them is not in how they work. It is that one is an approved medicine and the other is still in trials.

How they work

Both compounds act on incretin receptors, the receptors for gut hormones released after eating.

Tirzepatide is a dual agonist. It activates two receptors: GIP and GLP-1.

Retatrutide is a triple agonist. It activates the same two receptors plus a third, the glucagon receptor. Glucagon signalling increases energy expenditure and affects how the liver handles fat. That third target is the reason researchers expected retatrutide to produce larger effects.

Side by side

RetatrutideTirzepatide
ReceptorsGIP, GLP-1, glucagonGIP, GLP-1
StagePhase 3 trials under wayApproved medicine
Brand namesNoneMounjaro, Zepbound
Key trialPhase 2 (Jastreboff, NEJM 2023)SURMOUNT-1 (Jastreboff, NEJM 2022)
Trial length48 weeks72 weeks
Highest-dose result−24.2% at 12 mg−20.9% at 15 mg
Placebo−2.1%−3.1%
Approved in IndonesiaNoYes, since February 2026
Anti-dopingWADA S0, prohibitedMonitoring Program, not prohibited

Why these results cannot be compared directly

It is tempting to read the table and conclude that retatrutide produces more weight loss. The trials do not allow that conclusion.

  • They never met. No trial has compared retatrutide and tirzepatide against each other.
  • Different trial sizes. The retatrutide trial enrolled 338 people. SURMOUNT-1 enrolled 2,539.
  • Different lengths. 48 weeks versus 72 weeks.
  • Different stages. Phase 2 results often shrink when a compound reaches larger phase 3 trials, because phase 3 enrols broader populations.

What can be said is that retatrutide's phase 2 results were among the largest reported at that stage for any weight-management compound, and that its phase 3 programme will show whether they hold.

Side effects

Both compounds cause mostly gastrointestinal effects — nausea, diarrhoea, vomiting and constipation — most often while doses are increased. In the retatrutide trial, heart rate rose in a dose-related way, peaking at around 24 weeks. Tirzepatide's prescribing information carries a boxed warning about thyroid C-cell tumours based on rodent findings, a warning that applies across this drug class.

What neither does

Neither compound is a fat burner in the stimulant sense: their effect comes largely from reduced appetite and slower digestion. Weight tends to return when compounds in this class are stopped. And research-grade material of either is not the product tested in trials or sold under a brand name.

Frequently asked questions

Retatrutide's phase 2 results were larger than tirzepatide's phase 3 results, but the trials differed in size, length and stage, and the two have never been compared directly.

No. It is in phase 3 trials. Tirzepatide is approved as Mounjaro and Zepbound, including in Indonesia.

A dual agonist such as tirzepatide activates GIP and GLP-1 receptors. A triple agonist such as retatrutide also activates the glucagon receptor.

Retatrutide falls under WADA category S0. Tirzepatide is on WADA's Monitoring Program and is not prohibited.

Doses mentioned on this page are the arms of published trials, given to describe their results. They are not guidance.

Sources

  1. Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-hormone-receptor agonist retatrutide for obesity — a phase 2 trial. New England Journal of Medicine, 2023;389:514–526. Link
  2. Jastreboff AM, Aronne LJ, Ahmad NN, et al.. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 2022;387:205–216. Link
  3. World Anti-Doping Agency. The Prohibited List and Monitoring Program. WADA. Link

Related pages

...